Cargando…

Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report

BACKGROUND: Combined small cell lung cancer (c-SCLC) is a relatively rare subtype of SCLC, especially when SCLC is initially diagnosed and recurrent lesions are non-small cell lung cancer (NSCLC). Moreover, SCLC combined lung squamous cell carcinoma (LUSC) has few been reported. CASE PRESENTATION: H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhisheng, Zhang, Junling, Ge, Yunjie, Huang, Mengli, Wang, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968780/ https://www.ncbi.nlm.nih.gov/pubmed/36860892 http://dx.doi.org/10.2147/CMAR.S397711

Ejemplares similares

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma
por: Li, Xiaofen, et al.
Publicado: (2018)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
por: Teicher, Beverly A., et al.
Publicado: (2017)

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung
por: Janzic, Urska, et al.
Publicado: (2017)

Characterization and mechanisms of radioresistant lung squamous cell carcinoma cell lines
por: Pan, Lifang, et al.
Publicado: (2023)

Squamous Cell Carcinoma of the Lung
por: Suarez, Eric, et al.
Publicado: (2017)

Squamous cell carcinoma mimics small cell carcinoma of the lung: a case report
por: Kmeid, Michael, et al.
Publicado: (2020)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

Evaluation of the Prognostic Value of Long Noncoding RNAs in Lung Squamous Cell Carcinoma
por: Zhang, Xiaoting, et al.
Publicado: (2022)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
por: Wang, Jing, et al.
Publicado: (2023)

The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
por: Ho, Hsiang-Ling, et al.
Publicado: (2019)

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting
por: Zhou, Yi-Xin, et al.
Publicado: (2021)

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
por: Foy, Jean-Philippe, et al.
Publicado: (2022)

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Publicado: (2022)

CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma
por: Li, Ting, et al.
Publicado: (2020)

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
por: Italiano, Antoine, et al.
Publicado: (2021)

New first-line treatment strategies for advanced lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

Construction of a Two-Gene Immunogenomic-Related Prognostic Signature in Lung Squamous Cell Carcinoma
por: Zhang, Xiaoting, et al.
Publicado: (2022)

Small cell carcinoma of the lung in a patient with previously treated synchronous adenocarcinoma and squamous cell carcinoma
por: Ullah, Asad, et al.
Publicado: (2021)

Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report
por: Sun, Mengyao, et al.
Publicado: (2020)

Pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma
por: Zhang, Bin, et al.
Publicado: (2016)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Isolated Renal Metastasis from Primary Lung Squamous Cell Carcinoma with Synchronous Small Cell Lung Cancer
por: Numan, Laith, et al.
Publicado: (2019)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
por: Zhai, Chongya, et al.
Publicado: (2021)

High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation
por: LIU, LU, et al.
Publicado: (2023)

Small-sized peripheral squamous cell lung carcinoma with chest wall invasion
por: Otsuka, Shinya, et al.
Publicado: (2022)

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
por: Valencia, Karmele, et al.
Publicado: (2022)

Squamous Cell Carcinoma Occurring in Asbestosis of the Lung
por: Cureton, R. J. R.
Publicado: (1948)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

Mutational signatures in squamous cell carcinoma of the lung
por: Osoegawa, Atsushi, et al.
Publicado: (2021)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
por: Zhao, Yanjie, et al.
Publicado: (2020)

Gene profiling of metastatic small intestinal squamous cell carcinoma after lung squamous cell carcinoma surgery: a case report
por: Zhu, Fangchao, et al.
Publicado: (2022)

Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers
por: Wang, Yinhua, et al.
Publicado: (2021)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

Alterations in serum protein glycopatterns related to small cell lung cancer, adenocarcinoma and squamous carcinoma of the lung
por: Jia, Liyuan, et al.
Publicado: (2020)

Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma
por: Zhou, Bo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gf7n7ed9a5l9vdbf3dolhgh2vi